Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Gains from Investment Securities (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Gains from Investment Securities data on record, last reported at -$628000.0 in Q3 2025.

  • For Q3 2025, Gains from Investment Securities fell 245.37% year-over-year to -$628000.0; the TTM value through Sep 2025 reached $9.9 million, up 4411.87%, while the annual FY2024 figure was $9.6 million, 1936.58% up from the prior year.
  • Gains from Investment Securities reached -$628000.0 in Q3 2025 per MIRM's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $8.9 million in Q4 2024 and bottomed at -$1.2 million in Q4 2021.
  • Average Gains from Investment Securities over 5 years is $646888.7, with a median of $194026.0 recorded in 2022.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 473835.12% in 2022, then tumbled 3580.0% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at -$1.2 million in 2021, then soared by 98.75% to -$15000.0 in 2022, then crashed by 3580.0% to -$552000.0 in 2023, then skyrocketed by 1705.43% to $8.9 million in 2024, then tumbled by 107.09% to -$628000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were -$628000.0 in Q3 2025, $1.3 million in Q2 2025, and $356000.0 in Q1 2025.